Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targets (Metabolic Mediators) of Therapeutic Importance in Pancreatic Ductal Adenocarcinoma
Vikrant Rai, Swati Agrawal
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 22, pp. 8502-8502
Open Access | Times Cited: 11

Showing 11 citing articles:

Emerging Trends and Research Foci in Tumor Microenvironment of Pancreatic Cancer: A Bibliometric and Visualized Study
Kaiwen Wu, Ye Liu, Lei Liu, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 32
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation
Maria Serena Roca, Tania Moccia, Federica Iannelli, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 31
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma
Yexin Tong, Mingjun Sun, Lingli Chen, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 29
Decoding the Intricate Landscape of Pancreatic Cancer: Insights into Tumor Biology, Microenvironment, and Therapeutic Interventions
Antonella Argentiero, Alessandro Andriano, Ingrid Catalina Caradonna, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2438-2438
Open Access | Times Cited: 4
Borax Pentahydrate as a Promising Boron-Based Angiogenesis Inhibitor
Gönül Ulus, Emine Nur ÖZBEK, Hamza Yılmaz, et al.
Journal of Trace Elements in Medicine and Biology (2025) Vol. 89, pp. 127640-127640
Closed Access
Novel strategies to improve tumour therapy by targeting the proteins MCT1, MCT4 and LAT1
Yang Wang, Liuxin Qin, Weiwei Chen, et al.
European Journal of Medicinal Chemistry (2021) Vol. 226, pp. 113806-113806
Closed Access | Times Cited: 26
Mitochondrial Metabolism in Pancreatic Ductal Adenocarcinoma: From Mechanism-Based Perspectives to Therapy
Hafiza Padinharayil, Vikrant Rai, Alex George
Cancers (2023) Vol. 15, Iss. 4, pp. 1070-1070
Open Access | Times Cited: 7
Glycometabolic rearrangements–aerobic glycolysis in pancreatic ductal adenocarcinoma (PDAC): roles, regulatory networks, and therapeutic potential
Zhong Zhang, Haijun Zhang
Expert Opinion on Therapeutic Targets (2021) Vol. 25, Iss. 12, pp. 1077-1093
Closed Access | Times Cited: 11
Lysosome‑targeted drug combination induces multiple organelle dysfunctions and non‑canonical death in pancreatic cancer cells
Sumire Suzuki, Masato Ogawa, Masaya Miyazaki, et al.
Oncology Reports (2021) Vol. 47, Iss. 2
Open Access | Times Cited: 9
A Potential Prognostic Marker PRDM1 in Pancreatic Adenocarcinoma
Bo Zhou, Jie Zhang, Hongda Zhu, et al.
Journal of Oncology (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 2
Emerging agents for metastatic pancreatic cancer: spotlight on early phase clinical trials
Byung Woog Kang, Ian Chau
Expert Opinion on Investigational Drugs (2021) Vol. 30, Iss. 11, pp. 1089-1107
Closed Access | Times Cited: 2
Page 1

Scroll to top